Quarterly ResultMay 13, 2026, 04:28 PM
Rapid Micro Biosystems Q1 Revenue $8.0M, +11%; Placed 6 Growth Direct Systems
AI Summary
Rapid Micro Biosystems reported first quarter 2026 total revenue of $8.0 million, an 11.1% increase year-over-year, driven by strong product and consumable revenue growth. The company placed 6 Growth Direct systems, doubling placements from the prior year, and advanced its strategic collaboration with MilliporeSigma. Despite operational growth and reaffirmed full-year revenue and system placement guidance, the company reported an increased net loss of $14.3 million for the quarter.
Key Highlights
- Q1 2026 total revenue increased 11.1% to $8.0 million compared to $7.2 million in Q1 2025.
- The company placed 6 Growth Direct systems in Q1 2026, up from 3 systems in Q1 2025.
- Product revenue increased 36.0% to $5.6 million, and consumable revenue increased over 30% year-over-year.
- Recurring revenue grew 27.7% to $5.1 million, representing 63% of total revenue.
- Net loss for Q1 2026 was $14.3 million, or $0.31 per share, compared to $11.3 million ($0.26 per share) in Q1 2025.
- Full-year 2026 total revenue guidance reaffirmed at $37.0 million to $41.0 million.
- Full-year 2026 guidance for Growth Direct system placements reaffirmed at 30 to 38 systems.
- Cash, cash equivalents, short-term investments, and restricted cash were approximately $23 million as of March 31, 2026.